Trial Profile
Phase 1 Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells (CART22-65s) Alone and When Co-administered With Humanized Anti-CD19 Chimeric Antigen Receptor Redirected T Cells (huCART19) In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Mar 2022
Price :
$35
*
At a glance
- Drugs CAR-T cell therapies (Primary) ; CTL 119 (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 28 Jun 2021 Planned End Date changed from 1 Sep 2037 to 1 Jan 2036.
- 16 Dec 2020 Status changed from recruiting to active, no longer recruiting.
- 04 Nov 2020 Planned End Date changed from 1 Sep 2033 to 1 Sep 2037.